Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Hit early, hit hard! Closing the loop – Managing CKD in T2DM

Questionnaire

To access this module, please register or login:

Login or Register

Hit early, hit hard! Closing the loop – Managing CKD in T2DM
Hit early, hit hard! Closing the loop – Managing CKD in T2DM

Time limit: 0

Questionnaire Summary

0 of 10 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 10 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please read/watch the module carefully and try once more!
(Only two tries are allowed)
Congratulations on successfully completing this FREE CPD module!
- For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile
- For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.
Please note you will no longer receive a pass confirmation email. Your activity automatically downloads on to your deNovo Medica profile.
Visit your profile HERE to find all your CPD certificates and activities completed.

1
2
3
4
5
6
7
8
9
10

Current
Review
Answered
Correct
Incorrect

Question 1 of 10
1. Question
1. Among factors that drive CKD progression in T2DM are:
A. Elevated BP, intraglomerular pressure
Correct Incorrect Correct answer

B. Poor glycaemic control
Correct Incorrect Correct answer

C. Inflammation and fibrosis
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer
Question 2 of 10
2. Question
2. Despite advances in medications that inhibit the renin-aldosterone system and the advent of SGLT2is, many patients continue to experience progressive renal decline and an associated residual risk for adverse cardiorenal outcomes.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 3 of 10
3. Question
3. A treatment for management of CKD and T2DM that targets inflammation and fibrosis is:3. A treatment for management of CKD and T2DM that targets inflammation and fibrosis is:
A. ACEi/ARB
Correct Incorrect Correct answer

B. SGLT2i/GLP-1RA
Correct Incorrect Correct answer

C. Thiazide-like diuretics/CCB
Correct Incorrect Correct answer

D. Nonsteroidal MRA
Correct Incorrect Correct answer
Question 4 of 10
4. Question
4. Key findings of the FIDELITY programme investigating the effects of 10mg or 20mg finerenone OD compared with placebo in participants with CKD and T2DM include:
A. A 23% reduced risk of CKD progression
Correct Incorrect Correct answer

B. No difference in risk of cardiovascular death and total HHF
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 5 of 10
5. Question
5. The CONFIDENCE trial investigating the effects of 10mg or 20mg finerenone OD plus empagliflozin 10mg OD in participants with CKD and T2DM found greater reductions in UACR compared with:
A. Empagliflozin alone
Correct Incorrect Correct answer

B. Finerenone alone
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 6 of 10
6. Question
6. The percentage of CONFIDENCE trial participants experienced who hyperkalaemia leading to hospitalisation or death when using finerenone and/or empagliflozin was:
A. 0%
Correct Incorrect Correct answer

B. <1%
Correct Incorrect Correct answer

C. <5%
Correct Incorrect Correct answer

D. <10%
Correct Incorrect Correct answer
Question 7 of 10
7. Question
7. The identification of early-stage DKD is often difficult due to non-specific clinical signs and symptoms.
A. True
Correct Incorrect Correct answer

B. False
Correct Incorrect Correct answer
Question 8 of 10
8. Question
8. KDIGO recommendations for the screening and diagnosis of CKD are the assessment of:
A. Serum creatinine
Correct Incorrect Correct answer

B. UACR, or dipstick if unavailable
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 9 of 10
9. Question
9. In patients receiving treatment for diabetic nephropathy:
A. Restrict dietary intake of sodium and protein
Correct Incorrect Correct answer

B. Avoid nephrotoxic medications such as NSAIDs
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer
Question 10 of 10
10. Question
10. In patients with T2DM, intensive glucose control:
A. Slows the onset of microalbuminuria
Correct Incorrect Correct answer

B. Reduces progression to established nephropathy
Correct Incorrect Correct answer

C. Both of the above
Correct Incorrect Correct answer

D. None of the above
Correct Incorrect Correct answer

All Rights Reserved 2026 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?